Study of AMG 436 for MSI-H/dMMR Cancers
Part of Cancer clinical trials.
This study tests an experimental drug called AMG 436, alone or with other treatments, for people with advanced solid tumors that have a specific genetic change (MSI-H or dMMR). The goal is to see if the drug can shrink tumors and if it is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years of age or older.
- Your cancer must have a specific genetic marker called MSI-H or dMMR (your doctor can check).
- You need to have a tumor tissue sample available from a past surgery or biopsy, or be willing to have a new biopsy.
- Your cancer must be measurable on imaging scans (like CT or MRI).
- You should be able to do most daily activities (walk, light work, etc.) without help.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
This study tests a new drug called AMG 410 by itself or with other medicines in people whose cancer has a specific change in the KRAS gene. It is for advanced or metastatic solid tumors that have not responded to standard treatments or who have chosen not to take them.
This trial tests a new drug called MRG007 for people with advanced solid tumors that haven't responded to other treatments. The drug targets a protein called CDH17 on cancer cells; you need a tumor sample to check for it.
This trial tests a new drug called JMKX005425 for people with advanced solid tumors that have a specific genetic feature called MSI-H or dMMR. If you have this feature and your cancer has not responded to other treatments, this study may offer a new option.
This Phase 2 trial tests KN035 in people with advanced or spread-out tumors that have specific genetic markers (MSI-H or dMMR). If you qualify, the study team will look at how well the drug works and how it affects side effects in that group.
This trial tests an oral medication called MOMA-341 in people with advanced solid tumors that have high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR). It aims to see if the drug can help when prior immunotherapy hasn't worked or isn't available.
Hear when a new Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.